Canadian startup Encycle Therapeutics nabs C$2.85 mln

By Iris Dorbian — 4 months ago

Toronto-based drug discovery company Encycle Therapeutics has closed C$2.85 million in funding. The investors were Takeda Ventures Inc, Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund. Encycle is a University of Toronto spin-out.

Continue

ArmaGen Technologies Raises $17m Series A

By Angela Sormani — 3 years ago

ArmaGen Technologies has closed a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Venture Fund, joined by Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.

Continue

Takeda to Acquire Envoy

By Angela Sormani — 3 years ago

Takeda America Holdings is to acquire Envoy. Takeda America Holdings will acquire 100 percent of the equity in Envoy for total consideration of up to $140 million, which includes an up-front payment and progress-dependent, preclinical milestone payments. Envoy is a privately-held drug discovery company focused on finding new drugs with superior efficacy and fewer side effects than existing treatments. Takeda’s corporate venture arm, Takeda Ventures, participated in Envoy’s series A financing in October 2009.

Continue

Juventas Closes Series B

By Angela Sormani — 4 years ago

Cleveland, OH- based Juventas Therapeutics, a clinical-stage regenerative medicine company, has closed a $22.2 million Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures. All previous venture firms, including Fletcher Spaght Ventures, Reservoir Venture Partners and Early Stage Partners participated in the round. Also joining the syndicate are new […]

Continue